Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy MorphoSys stock | $28.34

Own MorphoSys stock in just a few minutes.

Fact checked

MorphoSys AG is a biotechnology business based in the US. MorphoSys shares (MOR) are listed on the NASDAQ and all prices are listed in US Dollars. MorphoSys employs 640 staff and has a market cap (total outstanding shares value) of USD$3.6 billion.

How to buy shares in MorphoSys

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for MorphoSys. Find the stock by name or ticker symbol: MOR. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until MorphoSys reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$28.34, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of MorphoSys, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of MorphoSys. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

MorphoSys share price

Use our graph to track the performance of MOR stocks over time.

MorphoSys shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$28.34
52-week rangeUSD$18.21 - USD$37.9609
50-day moving average USD$27.2771
200-day moving average USD$30.083
Wall St. target priceUSD$36.39
PE ratio 45.8797
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.2608

Buy MorphoSys shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy MorphoSys stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

MorphoSys price performance over time

Historical closes compared with the close of $28.34 from 2020-12-31

1 week (2021-01-07) -4.03%
1 month (2020-12-16) -0.39%
3 months (2020-10-16) 1.11%
6 months (2020-07-16) -15.38%
1 year (2020-01-16) -15.55%
2 years (2019-01-16) -4.03%
3 years (2018-01-13) N/A
5 years (2016-01-13) N/A

Is MorphoSys under- or over-valued?

Valuing MorphoSys stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MorphoSys's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

MorphoSys's P/E ratio

MorphoSys's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 46x. In other words, MorphoSys shares trade at around 46x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

MorphoSys financials

Gross profit TTM USD$59.7 million
Return on assets TTM 3.74%
Return on equity TTM 12.31%
Profit margin 21.17%
Book value $4.9028
Market capitalisation USD$3.6 billion

TTM: trailing 12 months

Shorting MorphoSys shares

There are currently 359,305 MorphoSys shares held short by investors – that's known as MorphoSys's "short interest". This figure is 3% up from 348,967 last month.

There are a few different ways that this level of interest in shorting MorphoSys shares can be evaluated.

MorphoSys's "short interest ratio" (SIR)

MorphoSys's "short interest ratio" (SIR) is the quantity of MorphoSys shares currently shorted divided by the average quantity of MorphoSys shares traded daily (recently around 56229.264475743). MorphoSys's SIR currently stands at 6.39. In other words for every 100,000 MorphoSys shares traded daily on the market, roughly 6390 shares are currently held short.

However MorphoSys's short interest can also be evaluated against the total number of MorphoSys shares, or, against the total number of tradable MorphoSys shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case MorphoSys's short interest could be expressed as 0% of the outstanding shares (for every 100,000 MorphoSys shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable MorphoSys shares, roughly 0 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against MorphoSys.

Find out more about how you can short MorphoSys stock.

MorphoSys share dividends

We're not expecting MorphoSys to pay a dividend over the next 12 months.

MorphoSys share price volatility

Over the last 12 months, MorphoSys's shares have ranged in value from as little as $18.21 up to $37.9609. A popular way to gauge a stock's volatility is its "beta".

MOR.US volatility(beta: 1.05)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MorphoSys's is 1.0527. This would suggest that MorphoSys's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

MorphoSys overview

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; Otilimab, an antibody for rheumatoid arthritis; MOR106, an antibody for inflammatory diseases and atopic dermatitis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site